Press Releases July 15, 2026 07:00 AM

Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026

Axogen to announce Q2 2026 financial results and host earnings call on July 29, 2026

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
AXGN

Axogen, Inc., a Nasdaq-listed company specializing in peripheral nerve repair technologies, will release its second quarter 2026 financial results on July 29, 2026, followed by a conference call and webcast for investors. The company continues to provide innovative surgical solutions for nerve restoration and maintains a broad product portfolio in this specialized medical sector.

Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
AXGN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Axogen is scheduled to report Q2 2026 financial results on July 29, 2026.
  • A conference call and webcast will follow the earnings release to discuss the results with investors.
  • The company focuses on developing and marketing peripheral nerve repair solutions with a comprehensive product line including Avance® and Axoguard® products.

ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.

Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event are available on the Investors page of the company's website at www.axogeninc.com.

About Axogen
Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.

Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.

Contact:
Axogen, Inc.
[email protected]


Risks

  • Financial results may fall short of market expectations, impacting stock performance.
  • Competition in the medical device and regenerative medicine sectors could affect market share.
  • Dependence on healthcare provider adoption and reimbursement policies influences sales and growth.

More from Press Releases

CNH Names Paul Dick, President, North America Nov 20, 2026 Harmony Biosciences to Participate in Upcoming Investor Conferences Nov 19, 2026 Pure Cycle Announces Record Financial Results For the Year Ended August 31, 2026 Nov 18, 2026 Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026